ID   HTh7
AC   CVCL_6289
SY   Hth7; HTh 7; HTh-7; Uhth-7; U-hth7; U-Hth7
DR   BTO; BTO_0005146
DR   cancercelllines; CVCL_6289
DR   CCRID; 3101HUMSCSP547
DR   CLS; 305128
DR   Cosmic; 1068622
DR   Cosmic; 1239969
DR   Cosmic; 1280043
DR   Cosmic; 1507376
DR   Cosmic; 1533553
DR   Cosmic; 1536129
DR   Cosmic; 1889008
DR   Cosmic; 2050367
DR   Cosmic; 2054111
DR   Cosmic; 2319851
DR   Cosmic; 2791085
DR   IARC_TP53; 21623
DR   Wikidata; Q54896655
RX   PubMed=3518877;
RX   PubMed=6220172;
RX   PubMed=17465858;
RX   PubMed=18713817;
RX   PubMed=21868764;
RX   PubMed=23833040;
RX   PubMed=25365311;
RX   PubMed=26680454;
RX   PubMed=30737244;
CC   Sequence variation: Mutation; HGNC; HGNC:7133; KMT2D; Simple; p.Gln4118Ter (c.12352C>T); Zygosity=Unspecified (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Homozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=30737244).
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Discontinued: CLS; 305128; true.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): PubMed=17465858; PubMed=18713817; PubMed=21868764; PubMed=25365311; PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 12 (PubMed=25365311)
ST   CSF1PO: 12,13 (PubMed=30737244)
ST   D13S317: 11,14
ST   D16S539: 9,13
ST   D18S51: 16
ST   D21S11: 29,30
ST   D3S1358: 14,15
ST   D5S818: 11
ST   D7S820: 8,11
ST   D8S1179: 12,13
ST   FGA: 20,23
ST   TH01: 9,9.3
ST   TPOX: 11
ST   vWA: 14 (PubMed=17465858; PubMed=21868764)
ST   vWA: 14,18 (PubMed=18713817; PubMed=25365311; PubMed=30737244)
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   74Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 25
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=17465858; DOI=10.1089/thy.2006.0246;
RA   Lee J.-J., Foukakis T., Hashemi J., Grimelius L., Heldin N.-E.,
RA   Wallin G., Rudduck C., Lui W.-O., Hoog A., Larsson C.;
RT   "Molecular cytogenetic profiles of novel and established human
RT   anaplastic thyroid carcinoma models.";
RL   Thyroid 17:289-301(2007).
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. 3rd, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690; PMCID=PMC3229662;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=25365311; DOI=10.1210/jc.2014-2359; PMCID=PMC4318896;
RA   Garg M., Okamoto R., Nagata Y., Kanojia D., Venkatesan S., Anand M.T.,
RA   Braunstein G.D., Said J.W., Doan N.B., Ho Q., Akagi T., Gery S.,
RA   Liu L.-Z., Tan K.-T., Chang W.J., Yang H.H., Ogawa S., Koeffler H.P.;
RT   "Establishment and characterization of novel human primary and
RT   metastatic anaplastic thyroid cancer cell lines and their genomic
RT   evolution over a year as a primagraft.";
RL   J. Clin. Endocrinol. Metab. 100:725-735(2015).
//
RX   PubMed=26680454; DOI=10.1186/s12885-015-1955-9; PMCID=PMC4683857;
RA   Kasaian K., Wiseman S.M., Walker B.A., Schein J.E., Zhao Y.-J.,
RA   Hirst M., Moore R.A., Mungall A.J., Marra M.A., Jones S.J.M.;
RT   "The genomic and transcriptomic landscape of anaplastic thyroid
RT   cancer: implications for therapy.";
RL   BMC Cancer 15:984.1-984.11(2015).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//